Quality Improvement Grant Request for Proposals: Optimizing Maternal RSV Immunization Delivery
Pfizer Inc.'s grant supports projects that improve and measure system-level delivery and equity of maternal RSV immunization in U.S. healthcare settings.
Funder: Pfizer Inc.
Due Dates: September 10, 2026 (Full application submission deadline)
Funding Amounts: $100,000–$200,000 per project; up to 18 months duration; total available budget $200,000.
Summary: Supports quality improvement projects to enhance maternal RSV immunization delivery, focusing on access, equity, and measurable outcomes in U.S. healthcare systems.
Key Information: Proposals must address system-level change and measurable outcomes; educational-only projects are lower priority.
Description
Pfizer Inc., in partnership with the Society for Maternal-Fetal Medicine (SMFM), is offering a competitive grant opportunity to support independent quality improvement (QI) initiatives aimed at optimizing maternal immunization, with a focus on respiratory syncytial virus (RSV) vaccination during pregnancy. The program targets implementation of evidence-based interventions that improve delivery, access, and uptake of maternal RSV immunization, particularly in underserved communities.
Projects should address provider–patient communication, care coordination, and structural or behavioral barriers impacting vaccine equity and uptake. Multidisciplinary collaborations are encouraged, and proposals should prioritize scalable, sustainable models that can demonstrate measurable improvements in immunization coverage and reduction of disparities.
